IGC
Income statement / Annual
Last year (2025), IGC Pharma, Inc.'s total revenue was $1.27 M,
a decrease of 5.50% from the previous year.
In 2025, IGC Pharma, Inc.'s net income was -$7.12 M.
See IGC Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
| Operating Revenue |
$1.27 M |
$1.35 M |
$911.00 K |
$397.00 K |
$898.00 K |
$4.07 M |
$5.12 M |
$2.19 M |
$580.37 K |
$6.37 M |
| Cost of Revenue |
$652.00 K
|
$612.00 K
|
$1.07 M
|
$203.00 K
|
$1.25 M
|
$3.96 M
|
$4.98 M
|
$2.11 M
|
$362.14 K
|
$5.52 M
|
| Gross Profit |
$619.00 K
|
$733.00 K
|
-$158.00 K
|
$194.00 K
|
-$349.00 K
|
$115.00 K
|
$132.00 K
|
$81.52 K
|
$218.24 K
|
$843.29 K
|
| Gross Profit Ratio |
0.49
|
0.54
|
-0.17
|
0.49
|
-0.39
|
0.03
|
0.03
|
0.04
|
0.38
|
0.13
|
| Research and Development Expenses |
$3.66 M
|
$3.77 M
|
$3.46 M
|
$2.33 M
|
$929.00 K
|
$1.01 M
|
$1.26 M
|
$137.00 K
|
$114.00 K
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.97 M
|
$3.52 M
|
$1.73 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$136.48 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.41 M
|
$6.76 M
|
$7.95 M
|
$13.29 M
|
$7.45 M
|
$5.97 M
|
$3.52 M
|
$1.87 M
|
$2.27 M
|
$2.70 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$29.06 K
|
$119.93 K
|
$1.05 M
|
| Operating Expenses |
$8.07 M
|
$10.53 M
|
$11.41 M
|
$15.62 M
|
$8.38 M
|
$6.98 M
|
$4.78 M
|
$1.87 M
|
$2.27 M
|
$3.75 M
|
| Cost And Expenses |
$8.72 M
|
$11.14 M
|
$12.48 M
|
$15.83 M
|
$9.62 M
|
$10.94 M
|
$9.76 M
|
$3.98 M
|
$2.63 M
|
$9.27 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.82 K
|
$121.68 K
|
$2.09 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$30.74 K
|
$223.46 K
|
$213.93 K
|
| Depreciation & Amortization |
$618.00 K
|
$637.00 K
|
$657.00 K
|
$651.00 K
|
$478.00 K
|
$144.00 K
|
$59.00 K
|
$19.41 K
|
$396.35 K
|
$728.74 K
|
| EBITDA |
-$6.83 M |
-$9.16 M |
-$10.85 M |
-$14.37 M |
-$8.33 M |
-$6.72 M |
-$4.58 M |
-$1.74 M |
-$1.22 M |
-$1.89 M |
| EBITDA Ratio |
-5.37
|
-6.81
|
-11.91
|
-36.18
|
-9.28
|
-1.65
|
-0.9
|
-0.79
|
-2.1
|
-0.3
|
| Operating Income Ratio |
-5.86
|
-7.28
|
-12.7
|
-38.86
|
-9.71
|
-1.69
|
-0.91
|
-0.82
|
-3.54
|
-0.46
|
| Total Other Income/Expenses Net |
$325.00 K
|
-$3.20 M
|
$65.00 K
|
$412.00 K
|
-$87.00 K
|
-$451.00 K
|
$548.00 K
|
$2.95 K
|
$215.96 K
|
$72.34 K
|
| Income Before Tax |
-$7.12 M
|
-$13.00 M
|
-$11.51 M
|
-$15.02 M
|
-$8.81 M
|
-$7.32 M
|
-$4.10 M
|
-$1.79 M
|
-$1.84 M
|
-$2.83 M
|
| Income Before Tax Ratio |
-5.6
|
-9.67
|
-12.63
|
-37.82
|
-9.81
|
-1.8
|
-0.8
|
-0.81
|
-3.17
|
-0.44
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.00 K
|
$464.00
|
$14.43 K
|
$579.00
|
| Net Income |
-$7.12 M
|
-$13.00 M
|
-$11.51 M
|
-$15.02 M
|
-$8.81 M
|
-$7.32 M
|
-$4.10 M
|
-$1.79 M
|
-$1.87 M
|
-$2.81 M
|
| Net Income Ratio |
-5.6
|
-9.67
|
-12.63
|
-37.82
|
-9.81
|
-1.8
|
-0.8
|
-0.81
|
-3.22
|
-0.44
|
| EPS |
-0.0931 |
-0.22 |
-0.22 |
-0.3 |
-0.21 |
-0.19 |
-0.12 |
-0.06 |
-0.07 |
-0.17 |
| EPS Diluted |
-0.0931 |
-0.22 |
-0.22 |
-0.3 |
-0.21 |
-0.19 |
-0.12 |
-0.06 |
-0.07 |
-0.17 |
| Weighted Average Shares Out |
$76.52 M
|
$58.84 M
|
$52.58 M
|
$49.99 M
|
$41.96 M
|
$39.49 M
|
$35.39 M
|
$27.94 M
|
$25.66 M
|
$16.39 M
|
| Weighted Average Shares Out Diluted |
$76.52 M
|
$58.84 M
|
$52.58 M
|
$49.99 M
|
$41.96 M
|
$39.49 M
|
$35.39 M
|
$27.94 M
|
$25.66 M
|
$16.39 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
